Maeve is partner in the Corporate and M&A Group. Maeve advises on public and private mergers and acquisitions, joint ventures, private equity investments, equity capital markets and corporate reorganisations.
Maeve advises on both domestic and cross border transactions across various industries.
Maeve was previously based in the London and New York offices of Arthur Cox and also advises international clients on inward investment and corporate governance matters.
Relevant Experience
- Advising CPA Ireland on its amalgamation with Chartered Accountants Ireland by way of scheme of arrangement under Part 9 of the Companies Act 2014
- Advising Tuner Construction Company, a subsidiary of HOCHTIEF AG, on its acquisition of Dornan Engineering Group
- Advising Archer Hotel Capital on the acquisition of Shelbourne Hotel, and on its previous acquisition of the Conrad Hotel
- Advising Musgrave Group on multiple corporate transactions
- Advising Glanbia plc on the sale of its shareholding in Glanbia Cheese to Leprino Foods Company and on the disposal of its 40% interest in Glanbia Ireland DAC to Glanbia Co-operative Society Limited
- Advising AviLease on the acquisition of Standard Chartered’s global aviation leasing business
- Advising a search fund led by Mission Spring Ventures and Pacific Lake Partners on its acquisition of ETU, a leading immersive and simulation based learning provider
- Advising InfraVia Capital Partners on its investment of a 49.9% stake in Fibre Networks Ireland Holdings Limited, a dedicated joint venture fibre company with eir focused on the deployment of fibre-to-the-home across the Republic of Ireland (M&A Joint Venture Deal of the Year 2023, Finance Dublin)
- Advising Total Produce plc on its combination with Dole Food Company, Inc. and the successful IPO of Dole plc (ECM Deal of the Year 2022, Finance Dublin)
- Advising Greenergy International Limited on its acquisitions in Ireland, including Inver Energy Limited and Amber Oil
- Advising Novozymes A/S on its acquisition of PrecisionBiotics
- Advising Allergan plc on its $63 billion merger with AbbVie
